» Articles » PMID: 27093186

Genomic Landscape Survey Identifies SRSF1 As a Key Oncodriver in Small Cell Lung Cancer

Abstract

Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however, much still remains unknown, particularly in the Asian patient population. Here we conducted whole exome sequencing (WES) and transcriptomic sequencing of primary tumors from 99 Chinese SCLC patients. Dysregulation of tumor suppressor genes TP53 and RB1 was observed in 82% and 62% of SCLC patients, respectively, and more than half of the SCLC patients (62%) harbored TP53 and RB1 mutation and/or copy number loss. Additionally, Serine/Arginine Splicing Factor 1 (SRSF1) DNA copy number gain and mRNA over-expression was strongly associated with poor survival using both discovery and validation patient cohorts. Functional studies in vitro and in vivo demonstrate that SRSF1 is important for tumorigenicity of SCLC and may play a key role in DNA repair and chemo-sensitivity. These results strongly support SRSF1 as a prognostic biomarker in SCLC and provide a rationale for personalized therapy in SCLC.

Citing Articles

NUMB alternative splicing and isoform-specific functions in development and disease.

Dho S, Othman K, Zhang Y, McGlade C J Biol Chem. 2025; 301(3):108215.

PMID: 39863103 PMC: 11889595. DOI: 10.1016/j.jbc.2025.108215.


Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.

Tzaban S, Stern O, Zisman E, Eisenberg G, Klein S, Frankenburg S Front Immunol. 2025; 15():1490035.

PMID: 39845971 PMC: 11752881. DOI: 10.3389/fimmu.2024.1490035.


Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review.

Zhang C, Yang C, Shi Q Cancer Manag Res. 2025; 17():65-82.

PMID: 39830995 PMC: 11742633. DOI: 10.2147/CMAR.S495006.


Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer.

Jiang S, Tang Y, Ma F, Niu Y, Sun L Oncol Res. 2024; 33(1):213-224.

PMID: 39735674 PMC: 11671408. DOI: 10.32604/or.2024.046895.


Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.

Wang Z, Yu H, Bao W, Qu M, Wang Y, Zhang L Proc Natl Acad Sci U S A. 2024; 121(40):e2402741121.

PMID: 39320917 PMC: 11459144. DOI: 10.1073/pnas.2402741121.


References
1.
Cappuzzo F, Hirsch F, Rossi E, Bartolini S, Ceresoli G, Bemis L . Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(9):643-55. DOI: 10.1093/jnci/dji112. View

2.
Park M, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R . FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009; 145(2):198-206. DOI: 10.1111/j.1365-2141.2009.07607.x. View

3.
Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

4.
Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B . S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013; 3(1):103-15. PMC: 5021319. DOI: 10.1016/j.celrep.2012.11.020. View

5.
Yu J, Wu W, Li X, He J, Li X, Ng S . Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2014; 64(4):636-45. PMC: 4392212. DOI: 10.1136/gutjnl-2013-306620. View